Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVIHepC1 Vaccine Trial in Healthy Adults
NCT07237282Phase 1Not yet recruiting
- Sponsor
- University of Alberta
- Start
- Jan 2027
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hepatitis C (HCV) (2 arms), sponsored by University of Alberta. Primary endpoint: Adverse Events at 6 months. Planned start Jan 2027; status: not yet recruiting.
02
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT07237282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07237282.